Preferred Label : Ruzaltatug Rezetecan;
NCIt synonyms : Anti-HER3 ADC SHR-A2009; Anti-HER3 Antibody-drug Conjugate SHR-A2009;
NCIt definition : An antibody-drug conjugate (ADC) composed of ruzaltatug, an immunoglobulin G1 (IgG1)
human monoclonal antibody directed against human epidermal growth factor receptor
3 (HER3; ErbB3), conjugated, via a cleavable peptide linker, to rezetecan, an exatecan
derivative and cytotoxic DNA topoisomerase I inhibitor, with potential antineoplastic
activity. Upon administration of ruzaltatug rezetecan, the anti-HER3 antibody moiety
targets and binds to HER3 expressed on tumor cells. Upon binding, internalization
and linker cleavage, rezetecan targets and binds to DNA topoisomerase I, thereby stabilizing
the cleavable complex between topoisomerase I and DNA and resulting in DNA breaks,
inhibition of DNA replication and apoptosis in HER3-expressing tumor cells. HER3,
a member of the epidermal growth factor receptor (EGFR) family of receptor tyrosine
kinases, is frequently overexpressed in tumors.;
UNII : QZA4R4JG2Z;
CAS number : 2981438-67-7;
Molecule name : SHR-A2009; SHR A2009;
NCI Metathesaurus CUI : CL1921234;
Origin ID : C202278;
UMLS CUI : C5907971;
Semantic type(s)
- concept_is_in_subset
- has_target
